New Journey Health Technology GroupLTD Valuation
Is 002219 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 002219 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 002219 (CN¥2.76) is trading above our estimate of fair value (CN¥0.01)
Significantly Below Fair Value: 002219 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 002219?
Key metric: As 002219 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 002219's PS Ratio? | |
|---|---|
| PS Ratio | 2.5x |
| Sales | CN¥3.76b |
| Market Cap | CN¥9.38b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.9x |
| Enterprise Value/EBITDA | 25.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 002219's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.1x | ||
301293 Sanbo Hospital Management Group | 6.7x | n/a | CN¥9.5b |
300143 INKON Life Technology | 4x | 16.3% | CN¥6.4b |
301239 Chengdu Bright Eye Hospital Group | 2.7x | 18.5% | CN¥7.4b |
000516 Xi'an International Medical Investment | 2.7x | 21.6% | CN¥13.4b |
002219 New Journey Health Technology GroupLTD | 2.5x | n/a | CN¥9.4b |
Price-To-Sales vs Peers: 002219 is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (4.1x).
Price to Sales Ratio vs Industry
How does 002219's PS Ratio compare vs other companies in the CN Healthcare Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
600998 Jointown Pharmaceutical Group | 0.2x | 8.0% | US$3.72b |
000028 China National Accord Medicines | 0.2x | 5.7% | US$2.22b |
000950 C.Q. Pharmaceutical Holding | 0.1x | 10.1% | US$1.37b |
000078 Shenzhen Neptunus Bioengineering | 0.2x | n/a | US$1.05b |
| 7 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 002219 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the CN Healthcare industry average (1.9x).
Price to Sales Ratio vs Fair Ratio
What is 002219's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 002219's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shenzhen Lifotronic Technology
CN¥7.1b
Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.
688389
CN¥16.51
7D
-1.3%
1Y
-30.9%
iRay Technology
CN¥16.1b
Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.
688301
CN¥112.93
7D
-5.6%
1Y
-30.5%
Truking Technology
CN¥4.7b
Engages in medical equipment business in China and internationally.
300358
CN¥8.01
7D
3.2%
1Y
-32.9%